Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

BACKGROUND: Secukinumab demonstrated superior efficacy over ustekinumab in the treatment of moderate to severe plaque psoriasis over 16 weeks in the CLARITY study and over 52 weeks in the CLEAR study. OBJECTIVE: To compare the efficacy and safety of secukinumab vs. ustekinumab over 52 weeks in CLARI...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Eur Acad Dermatol Venereol
Main Authors: Bagel, J., Blauvelt, A., Nia, J., Hashim, P., Patekar, M., de Vera, A., Ahmad, K., Paguet, B., Xia, S., Muscianisi, E., Lebwohl, M.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2020
Fag:
Psoriasis
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7818402/
https://ncbi.nlm.nih.gov/pubmed/32365251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.16558
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker